'This research study is something that I can do personally to benefit ... humanity,' said one volunteer. Thousands more are needed.
A preliminary assessment of how Moderna's phase 3 trial is progressing is expected after researchers record the first 50 cases of COVID-19 among the participants. That could be sometime this fall or winter.
What these trials won't be able to answer, however, is how long immunity might last."It's one of the great unknowns," Hoge said. Moderna's vaccine is likely to require two doses, but it's possible a third will be necessary. Essink said his team is"looking for higher-risk patients, for more severe disease." That includes people of different ages and races, as well as those with comorbidities, such as heart disease, Type 2 diabetes and other risk factors.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Moderna's COVID-19 vaccine candidate moves into late-stage trialModerna Inc said on Monday it has started a U.S. government-backed late-stage trial for its COVID-19 vaccine candidate, the first to be implemented under the Trump administration's Operation Warp Speed anti-coronavirus program.
続きを読む »
Enrollment in Moderna's COVID-19 vaccine trial to complete by end of summer: FauciThe top U.S. infectious diseases expert Dr Anthony Fauci said on Monday enrollment in Moderna Inc's late-stage COVID-19 vaccine trial is expected to be finished by the end of summer this year. Data readouts from the trial, which enrolled the first of 30,000 trial participants on Monday, could occur by November or even earlier, Fauci said in a media call discussing the late-stage study.
続きを読む »
Moderna's Covid-19 vaccine put to final test in biggest trial yetThe experimental drug, developed by the US National Institutes of Health and Moderna, will be tried on 30,000 volunteers in the US who won't know if they're getting the real shot or a placebo in order to see which group experiences more infections.
続きを読む »
Phase 3 clinical trial of investigational vaccine for COVID-19 beginsToday NIH announced the launch of a Phase 3 clinical trial to test candidate vaccine mRNA-1273, developed by NIH, NIAIDNews, and moderna_tx, to prevent COVID19. ACTIV supported the protocol development and Operation WarpSpeed provided funding.
続きを読む »
Virus vaccine put to final test in thousands of volunteersThe world’s biggest COVID-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government -- one of several candidates in the...
続きを読む »
Moderna skyrockets 11% after receiving additional $472 million of funding, starting Phase 3 trial of COVID-19 vaccine | Markets InsiderModerna on Sunday announced it received a commitment of up to $472 million in additional funding from its contract with the Biomedical Advanced ...
続きを読む »